ReviewCurrent rheumatology reports2025
Updates on the Role of DXA in the Evaluation and Monitoring of Osteoporosis.
Review in Current rheumatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of osteoporosis and low bone mass in men with prostate cancer: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Research trends and hotspots in osteoporosis associated with gas molecules and related factors: a bibliometric analysis.Medical gas research · 2026Article
- Fragility fracture risk prediction using quantitative magnetic resonance and Vertebral Bone Quality scoring beyond density.World journal of methodology · 2026Review
- Adjunct Tendon Vibration and Bone Outcomes in Older Adults with Osteoporosis: A 12-Month Prospective Cohort Study.Journal of clinical medicine · 2026Article
- A Novel Dual-Energy X-Ray Absorptiometry Protocol for the Proximal Humerus Reveals a Fatty Infiltration Dependent Reduction in Bone Mineral Density.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026Article
- Development of Functional Performance, Bone Mineral Density, and Back Pain Under Specific Pharmacological Osteoporosis Therapy in an Elderly, Multimorbid Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Research progress on the mechanisms by which gut microbiota dysbiosis remodels the bone marrow neuroimmune microenvironment to drive age-related osteoporosis.Frontiers in immunology · 2026Review
- Bone microarchitecture and strength in obese women with and without polycystic ovary syndrome (PCOS): a peripheral quantitative computed tomography (pQCT) study.Frontiers in endocrinology · 2026Article
- Development and evaluation of a machine learning based risk prediction model for osteoporosis.Frontiers in molecular biosciences · 2026Article
- Sex-Specific Biological Predictors for Identifying Individuals With Low Bone Mineral Density Using the Taiwan Biobank Database.Journal of osteoporosis · 2026Article
- Development and validation of a robust logistic regression model for predicting osteoporosis in older people.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewOsteoporosis, the most common metabolic bone disease and a global health problem, is the result of abnormal bone architecture and bone loss, leading to bone fragility and an increased risk of fractures. A fragility or low-trauma fracture is the first clinical sign of osteoporosis and is typically associated with a significant risk of future fractures. Practical screening tools and guidelines are critical for fracture prevention. Dual X-ray absorptiometry (DXA) is the gold standard for risk stratification and diagnosis of osteoporosis. In this review, we report recent advances in in DXA screening and bone density evaluation for patients at risk of fragility fracture. RECENT
findingsDXA measures bone density as an absolute measure (g/cm2) and also reports the patient's bone mineral density (BMD) as a comparison to a standard population, which is the basis of the World Health Organization (WHO) classification for osteoporosis. DXA also provides vertebral fracture assessment (VFA), an additional tool to assess vertebral fracture presence and increased fracture risk. Understanding the methodology, reporting, and limitations of DXA use is critical for appropriate utilization of the test. BMD is validated as a predictor of fracture risk and may be used with or without clinical risk factors as part of the FRAX fracture risk assessment tool to accurately assess an individual's fracture risk. In this review, we discuss the role of DXA in screening, diagnosis, and treatment of osteoporosis. We include FRAX and its limitations, trabecular bone score (TBS), quantitative computed tomography (qCT) the American College of Rheumatology (ACR) updates on the management of glucocorticoid-induced osteoporosis, the updated International Society of Clinical Densitometry (ISCD) Position Statements, and report the key features of DXA testing, reporting, and utilization in clinical practice. DXA plays a critical role in BMD evaluation and fracture risk assessment. Appropriate utilization of this tool in clinical practice, through accurate interpretation and application of results, is essential for effective fracture prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.